Search PubMedSearch

PubMed · 3061069

[Combined immunologic deficiency].

Abstract

In the last 20 years 32 patients with severe combined immunodeficiency (SCID) were treated at our department. The clinical and immunological findings in these patients are presented. In connection with these patients, the recent WHO classification on combined immunodeficiency diseases and the pathogenesis in several forms of SCID, as far as is known, are discussed. SCID appears to represent a very heterogeneous group of disorders, which is affirmed by the findings in several of our patients. At this moment bone marrow transplantation (BMT) is the only way to cure patients with SCID. Without this treatment the prognosis of these patients is very poor. After BMT complete recovery is achieved for the majority of patients, even in the absence of a genotypically HLA identical donor. Besides the therapeutic aspects of SCID the recent developments with regard to carrier-detection and antenatal diagnosis are briefly discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E J Gerritsen, H van den Berg, R L Langlois van den Bergh, P T Schellekens, M J van Tol, L J Dooren, J M Vossen. 1988. [Combined immunologic deficiency].. https://pubmed.ncbi.nlm.nih.gov/3061069/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Autologous blood transfusion in Auckland.

AIMS: To review autologous blood collection and transfusion practice in Auckland over the last five years. METHOD: Records of autologous blood collections were obtained from blood collection centre records and results of transfusions on patients from hospital notes. RESULTS: One hundred and sixty-four units of blood were collected from 77 patients. Seventy-five percent of the units collected were transfused. Most autologous blood was transfused to private hospital patients. Only 8% of patients required homologous blood. CONCLUSIONS: There has been a slow increase of autologous blood collection and transfusion in the Auckland area, as well as in the rest of New Zealand. The present risks of homologous transfusion, particularly since the introduction of hepatitis C testing, appear very low. A further expansion of the present autologous blood programme would entail increased expenditure and it is suggested that a critical cost benefit analysis would be useful before the programme is expanded.

Blood Transfusion